-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

Benzinga·10/15/2026 10:10:23
Listen to the news
Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $275 price target.